Bloating is one of the most common side effects of GLP-1 injection treatments, including semaglutide (Wegovy) and tirzepatide (Mounjaro)
If the drugs are directly both improving weight reduction and cancer reduction, then we need to double down. Ganta wonders the same thing about the drugs apparent positive effects on several conditions, from dementia to sleep apnea: Is it that obesity is causing or contributing to the problem [and that weight loss is causing the improvement], or is the medication directly having an impact through a different mechanism? She hopes there will be more research to parse this out in the years to come
Hashmi, thank you so much for joining us
These are illustrated in figure 18
Pancreatitis Though rare, inflammation of the pancreas (known as pancreatitis) has been reported in some GLP-1 users
Its hard to think, if its 2030, and we have many of these medicines that weve proven the benefits for chronic diseases and the government said its worth it after this two-year pilot theyre doing its hard to think of too many employers who would say, Thats not for me, Ricks told me
